Factors Affecting the Price of VANFLYTA

Vanflyta (quizartinib), used for acute myeloid leukemia, has a price determined by multiple factors. High R&D costs are a major factor as developing this drug for a serious condition like leukemia requires extensive research and clinical trials.

Since it's a brand - name drug without generics yet, Daiichi Sankyo's patent protection allows for a relatively high price.  Production costs, including specialized manufacturing and quality control, also contribute.

Geographical location matters a great deal. In different countries, due to diverse healthcare policies, import tariffs, and distribution channels, prices vary significantly. Market demand from patients with FLT3 - ITD - positive AML also impacts the price. Insurance coverage further influences the out - of - pocket cost for patients.